NAD+ (and NMN / NR)

NAD+ is a coenzyme central to energy metabolism and cellular repair that declines with age. Supplements and IV products aim to raise it, but most longevity claims remain preliminary.

What it is

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, essential for converting food into cellular energy and for enzymes involved in DNA repair and signalling. NAD+ levels are widely reported to fall with age, driving interest in whether raising them could influence ageing. Because NAD+ itself is poorly absorbed by mouth, most products use precursors the body converts into NAD+ — NMN (nicotinamide mononucleotide), NR (nicotinamide riboside), and forms of vitamin B3. NAD+ is also sold directly as an IV infusion through some clinics.

How it works

NAD+ shuttles electrons in metabolism and acts as required "fuel" for enzymes called sirtuins and PARPs, involved in cellular stress responses and DNA repair. The theory behind NAD+ "boosting" is that restoring youthful levels might support these maintenance systems. Human studies confirm oral NMN and NR can raise blood NAD+ levels. Whether that measurable increase translates into meaningful health or longevity benefits is a separate, still-open question.

What the evidence says

Human trials consistently show NMN and NR increase NAD+ levels and are generally well tolerated over the periods studied. Beyond that, evidence is mixed and mostly early-stage. Some small trials report modest effects (for example a 2024 study where 250 mg/day NMN over 12 weeks in older adults was associated with maintained walking speed and better self-reported sleep), while other measures show inconsistent results. Much of the excitement traces to animal research, which does not reliably predict human outcomes. Clear evidence that NMN or NR slows human ageing or extends lifespan does not currently exist. NAD+ IV products in particular have very limited controlled-trial data.

Legal & regulatory status in Australia

This area changed recently. From 10 December 2025, NMN became a permissible ingredient in Listed Medicines (AUST L) under the TGA's Permissible Ingredients Determination, with conditions — adult use only, a maximum 500 mg/day, and not for pregnancy or breastfeeding. NAD+, NAD and NADH (oral) remain not permitted as listed-medicine ingredients. Compounded NAD+ (IV or injection) is supplied by some clinics and compounding pharmacies on prescription — this is not the same as a TGA-approved, ARTG-registered product. Regulatory status can change; confirm the current position with a registered pharmacist or doctor.

Risks & considerations

Oral NMN/NR are generally well tolerated in trials, but long-term safety data are limited and product quality and dosing vary widely. IV and injectable NAD+ carry the added risks of any infusion (infection, reactions) and reported side effects including nausea, chills and fatigue. Theoretical concerns exist about whether raising NAD+ could affect cell-growth pathways — unresolved, and a reason to involve a doctor.

What to ask a doctor

• Is there any human evidence that this would help my specific goal or condition?
• Do any of my medications or health conditions make this unsuitable?
• For IV/injectable NAD+: what are the infusion risks, and is the product appropriately sourced and compounded?
• How would we monitor for benefit or harm, and when would we stop?

FAQ

Q: Is NMN now legal as a supplement in Australia? A: As of 10 December 2025 NMN can be used in Listed Medicines under specific TGA conditions (adult, ≤500 mg/day, not in pregnancy/breastfeeding). A registered pharmacist can confirm whether a product complies. Q: Is raising NAD+ proven to slow ageing? A: No. Supplements can raise NAD+ levels, but robust human evidence that this slows ageing or extends lifespan does not currently exist. Q: Are NMN, NR and IV NAD+ interchangeable? A: No. They differ in form, absorption, evidence base and regulatory status — worth discussing with an AHPRA-registered doctor.